

AD _____

Award Number: DAMD17-98-1-8488

TITLE: A Novel Strategy for Targeting Therapeutic Retroviral Vectors
Specifically to Prostate Cancer Cells

PRINCIPAL INVESTIGATOR: John Young, Ph.D.

CONTRACTING ORGANIZATION: Harvard University
Boston, Massachusetts 02138

REPORT DATE: September 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20000608 156

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 1999	3. REPORT TYPE AND DATES COVERED Annual (01 Sep 98 - 31 Aug 99)	
4. TITLE AND SUBTITLE A Novel Strategy for Targeting Therapeutic Retroviral Vectors Specifically to Prostate Cancer Cells			5. FUNDING NUMBERS DAMD17-98-1-8488	
6. AUTHOR(S) John Young, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Harvard University Boston, Massachusetts 02138 e-mail: young@oncology.wisc.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release distribution unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) We are developing a system that will be useful for targeting therapeutic retroviral vectors specifically to prostate cancer cells using novel retroviral receptor-ligand bridge proteins that bind to specific cell surface ligand receptors. Using bridge proteins comprised of the TVA or TVB receptors (for subgroups A or B avian leukosis viruses (ALV), respectively), fused to human epidermal growth factor (EGF), viral targeting was achieved by preloading the bridge proteins onto cell surface EGF receptors or virions. In addition, we have demonstrated increased levels of viral vector targeting by incorporating selected amino acid substitutions into TVA-EGF. We have also generated a bridge protein comprised of TVA fused to neuregulin (NRG) which binds specifically to cell surface NRG receptors. These receptors are often up-regulated on prostate cancer cells and thus represent an attractive target for this method of therapeutic gene delivery. We have also shown that it is possible to target retroviral infection through the use of a bridge protein comprised of TVA fused to a single chain antibody specific for a mutant form of the EGF receptor that is found exclusively on cancer cell types. Thus, this appears to be a highly versatile and general viral targeting approach.				
14. SUBJECT TERMS Prostrate Cancer Retrovirus, Gene Therapy			15. NUMBER OF PAGES 20	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

4. Table of Contents

Page 1.	Cover Page
Page 2.	(SF) 298 Report Documentation Page
Page 3.	Foreword
Page 4.	Table of Contents
Page 5.	Introduction
Pages 6-12	Body
Page 13.	Key Research Accomplishments Reportable Outcomes Conclusions References
Pages 14-20	Appendices

5. Introduction

The goal of the proposed research is to use a novel technology that we have developed, involving retroviral receptor-ligand bridge proteins, to specifically target retroviral vectors to prostate cancer cells. These bridge proteins act to target viral infection by a) binding to a specific molecule on the target cell surface and b) binding to retroviral envelope (Env) glycoproteins and stimulating the fusogenic functions of these proteins leading to viral entry. The goal of this work is to target viral infection to prostate cancer cells by designing retroviral receptor-ligand bridge proteins that will bind to markers that are expressed either preferentially or exclusively on the surfaces of prostate cancer cells.



6. Body

We have made significant progress in our attempts to develop retroviral receptor-ligand bridge protein technology for targeting therapeutic retroviral vectors to prostate cancer cells as detailed below.

Task 1. To determine whether a soluble protein composed of the extracellular domain of TVA fused to the EGF-like region of neuregulin2 β (NRG) can target retroviral vector infection when attached to the ErbB3 receptor on the surfaces of prostate cancer cells

We have constructed the TVA-NRG gene and confirmed its production from transfected human 293 cells by immunoblotting analysis using an ALV-A SU-Ig protein as a binding probe. We have also used flow cytometric methods to demonstrate that the TVA-NRG protein binds specifically to cells that express neuregulin receptors (N234 cells, Fig. 1). The specificity of binding of TVA-NRG to neuregulin receptors on these cells was demonstrated by specific competition for binding with another NRG-containing bridge protein (TVB-NRG) but not by a bridge protein that contains a heterologous ligand (TVB-VEGF) (Fig. 2). Thus TVA-NRG has the desired cell type-dependent binding specificity. We are in the process of testing whether this protein can mediate infection specifically of cells that express neuregulin receptors.

Task 2. To determine whether a soluble protein composed of the extracellular domain of TVA fused to a single chain antibody that binds specifically to the TAG-72 protein can target retroviral infection to cells that express this surface marker.

To ask the larger question of whether TVA-bridge proteins can work if they contain a single chain antibody moiety in place of a ligand, we used as a model system a bridge protein with the extracellular domain of TVA fused to a single chain antibody (MR1) that binds to a mutant form (EGFRvIII) of the human epidermal growth factor receptor (EGFR). EGFRvIII is often found associated with human tumors and since it is not expressed on normal cell types it represents an attractive cell surface marker for this viral targeting system. A TVA-MR1 gene was constructed and expression of its protein in the extracellular supernatants of transfected human 293 cells was confirmed by immunoblotting using the ALV-A SU-Ig fusion protein as a binding probe. Also, we have shown that TVA-MR1 binds specifically to cells that express EGFRvIII (Fig. 3). Furthermore, the binding of TVA-MR1 to these cells was specifically competed in the presence of a peptide derived from EGFRvIII that corresponds to the epitope of the MR1 antibody, whereas a control peptide had no effect (Fig. 4). We have also shown that TVA-MR1 mediates efficient entry of ALV vectors into these cells. These results provide us with a great deal of confidence that we should achieve targeted viral infection using a TVA-based bridge protein that contains the single chain antibody directed against TAG-72.

Task 3. To determine whether increased levels of retroviral vector infection via ErbB3 and/or TAG-72, can be achieved by introducing into the soluble TVA fusion proteins, amino acid substitutions that increase the activity of the wild-type retroviral receptor.

To ask whether bridge proteins containing this class of amino acid substitution in TVA can work more efficiently than bridge proteins containing the wild-type TVA sequence, we have performed our initial experiments with TVA-EGF, the best-characterized retroviral receptor-ligand bridge protein. Altered TVA-EGF proteins were produced



bearing either the W48F or W48Y amino acid substitutions which are known to increase the activity of the wild-type TVA receptor. The altered proteins bearing these substitutions bound specifically to cells that express EGF receptors and mediated higher-than-wild-type levels of targeted viral infection into these cells (Fig.5). These data demonstrate that it is in fact possible to increase the level of targeted viral infection that can be obtained via TVA-ligand bridge proteins.

Task 4. To construct retroviral vectors containing "suicide genes" and to assess the efficiency of cell-killing mediated by these vectors following infection via ErbB3 and/or TAG-72.

Retroviral vectors encoding HSV-1 thymidine kinase and an activated form of the ICE protease have been generated and the corresponding viruses produced. These viruses are being tested for their cell-specific cell-killing activities.

In addition to the above results, we have also now demonstrated that it is possible to target retroviral vectors to cells using a retroviral receptor-ligand bridge protein (TVB-EGF) in a series of experiments that were funded in part by this grant. This work led to the following publication: Boerger A.L. et al. 1999. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. *Proc. Natl. Acad. Sci. (USA)* 96: 9867-9872. This research has opened up the possibility of using virions, instead of cells that are preloaded with these types of bridge proteins, for this viral targeting system and thus improves the potential utility of this approach.

*




Figure 1. Binding of TVA-NRG to N234 cells that express neuregulin receptors but not to NIH 3T3 cells that do not. N234 cells and NIH 3T3 cells were incubated with increasing amounts of TVA-NRG and the bound bridge protein was detected by flow cytometry using an ALV-A SU-Ig fusion protein and a FITC-conjugated secondary antibody.

*




Figure 2. Binding of TVA-NRG to N234 cells is specifically competed by a heterologous bridge protein that contains NRG (TVB-NRG) but not by a bridge protein that contains the ligand vascular endothelial growth factor (TVB-VEGF). N234 cells were incubated with medium containing no bridge protein or instead with medium that contains TVB-NRG or TVB-VEGF and the unbound bridge proteins were washed away. The cells were then incubated with TVA-NRG and the bound TVA-NRG protein was detected by flow cytometry as described in Fig. 1.

*




Figure 3. The TVA-MR1 bridge protein binds specifically to human 293T cells that express EGFRvIII but not to control human 293T cells that do not. Human 293T cells or human 293T cells that express EGFRvIII were incubated with increasing amounts of TVA-MR1 and the bound bridge protein was detected as described in Fig. 1.

*




Figure 4. TVA-MR1 binding is competed in the presence of a peptide corresponding to the epitope of the MR1 antibody but is not affected by a control peptide. TVA-MR1 containing supernatants were incubated with a test peptide corresponding to the epitope of MR1 (LEEKKGNVVTDH) or with a control peptide that had the same amino acid composition but is scrambled in sequence (YKELGVEVDNKHT). These preparations were then added to 293T-EGFR-vIII cells and the bound bridge protein was detected by flow cytometry as described in Fig. 1.

*

NUMBER OF β -GALACTOSIDASE-POSITIVE COLONIES




Figure 5. Higher-than-wild-type levels of targeted viral infection achieved using mutant forms of TVA-EGF containing W48F or W48Y amino acid substitutions in the TVA domain. Mouse M5 cells that express kinase-deficient EGF receptors were incubated with wild-type TVA-EGF or with the two mutant TVA-EGF proteins. The cells were then challenged with a retroviral vector that has the ALV-A Env protein and encodes β -galactosidase and the resultant number of β -galactosidase-positive cells was enumerated.



7. Key Research Accomplishments

- TVA-NRG has been produced and has the desired binding specificity for cells with neuregulin receptors.
- Cell-specific viral targeting has been achieved with a TVA-based bridge protein that contains a single chain antibody domain.
- Increased levels of targeted viral infection have been achieved using TVA-bridge proteins that contain specific mutations in the TVA domain known to increase the activity of the wild-type receptor
- Retroviral vectors containing suicide genes have been constructed
- It is now possible to target retroviral vectors to cells using retroviral receptor-ligand bridge proteins that are preloaded onto virion, as opposed to cell, surfaces.

8. Reportable Outcomes

Manuscripts

Boerger AL, Snitkovsky, S. and Young, J.A.T. (1999) Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. *Proc. Natl. Acad. Sci. (USA)* 96: 9867-9872

Presentations

Boerger AL (1999) Platform Presentation at the meeting "Vector Targeting Strategies for Therapeutic Gene Delivery" held at Cold Spring Harbor Laboratories, Cold Spring Harbor, New York March 11-14, 1999.

9. Conclusions

We have now made substantial progress in the development of the retroviral vector targeting system, especially in showing that it is possible to preload viral vectors with this type of bridge protein while retaining cell-specific targeting specificity. In addition, we have shown that it is also possible to achieve retroviral targeting through the use of bridge proteins that contain a single chain antibody in place of the ligand. This finding should increase the utility of this viral targeting approach and ultimately should be useful for using retroviral vectors to deliver therapeutic genes to prostate cancer cells.

10. References

All of the references that are pertinent to this progress report were included with the original application.

11. Appendices

1. Boerger AL, Snitkovsky, S. and Young, J.A.T. (1999) Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. *Proc. Natl. Acad. Sci. (USA)* 96: 9867-9872 (attached).
2. Boerger AL and Young JAT (1999) Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Abstract of presentation at the "Vector Targeting Strategies for Therapeutic Gene Delivery" meeting held at Cold Spring Harbor Laboratories, Cold Spring Harbor, New York March 11-14, 1999.

Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types

ADRIENNE L. BOERGER, SOPHIE SNITKOVSKY, AND JOHN A. T. YOUNG*

Department of Microbiology and Molecular Genetics, Harvard Medical School, 200 Longwood Avenue, Boston MA 02115

Edited by Inder M. Verma, The Salk Institute for Biological Studies, San Diego, CA, and approved June 21, 1999 (received for review February 12, 1999)

ABSTRACT Successful targeting methods represent a major hurdle to the use of retroviral vectors in cell-specific gene-delivery applications. We recently described an approach for retroviral targeting with a retroviral receptor-ligand bridge protein that was bound to the cognate cell-surface ligand receptors before viral challenge. We now report a significant improvement made to this viral targeting method by using a related bridge protein, designated TVB-EGF, comprised of the extracellular domain of the TVB receptor for subgroup B avian leukosis virus fused to epidermal growth factor (EGF). The most important activity of TVB-EGF was that it allowed specific viral entry when preloaded onto virions. Furthermore, virions preloaded with TVB-EGF were thermostable and could be produced directly from virus-packaging cells. These data suggest an approach for targeting retroviral vectors to specific cell types by using virions preloaded with a retroviral receptor-ligand bridge protein and indicate that these types of bridge proteins may be useful reagents for studying the normal mechanism of retroviral entry.

One of the major challenges facing retrovirus-based gene-delivery systems is in the development of approaches for efficiently targeting viral infection to only relevant cell types. A number of approaches have been tested in an effort to overcome this problem, including chemical modification of viral envelope (Env) proteins (1), the use of antibodies to bridge viral Env proteins with specific cell-surface molecules (2, 3), and the use of recombinant Env proteins containing cell-specific ligands or single-chain antibodies (4-17). Although these approaches have allowed for some degree of cell-type-specific viral entry, the level of infection observed is usually too low to be considered useful for most retrovirus-based gene-delivery applications (18, 19). Thus, there is clearly a need to develop new and improved methods for retroviral targeting.

We recently reported an approach for retroviral targeting with a retroviral receptor-ligand bridge protein (20). The bridge protein tested was comprised of the low density lipoprotein receptor-related extracellular domain of the TVA receptor for subgroup A avian leukosis virus (ALV-A) fused to human epidermal growth factor (EGF). When this bridge protein was added to the surfaces of cells that express EGF receptors (EGFR), these cells became highly susceptible to infection by ALV-A vectors (20). EGF was chosen as the prototype ligand to test this viral targeting approach, because its interaction with EGFR has been extensively characterized biochemically. Furthermore, EGFR is a relevant target for this method of retroviral vector delivery, because this receptor and other related receptors such as c-erbB-2 and c-erbB-3 are often overexpressed or mutated in solid human tumors (21).

Here, we show the functional activities of another type of bridge protein comprised of the tumor necrosis factor receptor-related extracellular domain of the TVB receptor for ALV-B fused to EGF. Most importantly, we show that it is possible to target retroviral vectors specifically to cells that express EGFR by preloading virions with the TVB-EGF bridge protein.

MATERIALS AND METHODS

Plasmids. A DNA fragment encoding the extracellular domain of TVBS3 (amino acid residues 1-155) was amplified by PCR from pBK7.6-2 template DNA (22) by using primers OAB2 (5'-CATTGTTCTCGAGATGCGCTCAGCTGCCCTCCG-3') and OAB5 (5'-CATTGTTCCGCCGTGAGTGGAGGAGCTGGAGGAG-3'). The PCR product was subcloned into the pCI expression vector (Promega) and ligated with a DNA fragment from plasmid pSS1 (20), encoding a glycine- and proline-rich linker region and human EGF. The resulting plasmid, pAB1, encodes TVB-EGF, and the sequence was validated by DNA sequencing (Department of Microbiology and Molecular Genetics DNA Sequencing Core Facility, Harvard Medical School).

A 2,208-bp *KpnI-BamHI* DNA fragment encoding a correctly spliced envA mRNA transcript (K. Zingler, L. Connolly, and J.A.T.Y., unpublished work) was subcloned into a modified version of the pCI expression plasmid to generate pAB6. Plasmid pAB7 encoding ALV-B Env was then generated by replacing the *XhoI-ApaI* env fragment of pAB6 with the corresponding 925-bp *XhoI-ApaI* fragment of the subgroup B RAV-2 env. Plasmid pMMP-nlslacZ, containing a murine leukemia virus (MLV) vector encoding β -galactosidase (lacZ); plasmid pMD.old.gag.pol, encoding the MLV proteins Gag and Pol (23); and plasmid pCMMP.GFP/neo, containing the gene encoding green fluorescent protein (GFP), were generous gifts from J.-S. Lee and R. C. Mulligan (Children's Hospital, Boston).

Cell Lines. Human 293 cells were obtained from the American Type Culture Collection. B82 cells are a clonal line of mouse L cells, which lack EGFR. As described in refs. 20, 24, and 25, these cells were transfected with plasmids encoding either a kinase-deficient EGFR or wild-type EGFR to generate clonal derivatives designated M5 and T23 cells, respectively. The M5:S3/T cell line was obtained after stable transfection of M5 cells with plasmids encoding FLAG-epitope tagged TVBS3 and TVBT, formerly SEAR, a subgroup E-specific ALV receptor (ref. 26 and H. Adkins and J.A.T.Y., unpublished work). Expression of TVBS3 in this cell line was confirmed by flow cytometry by using an ALV-B surface

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

PNAS is available online at www.pnas.org.

This paper was submitted directly (Track II) to the *Proceedings* office. Abbreviations: MLV, murine leukemia virus; ALV, avian leukosis virus; TVB, subgroup B ALV receptor; SU, surface envelope protein; EGF, epidermal growth factor; EGFR, EGF receptor; lacZ, β -galactosidase; GFP, green fluorescent protein.

*To whom reprint requests should be addressed. E-mail: john.young@hms.harvard.edu.

the same amount of virus under identical conditions. The cells were transferred to a 37°C incubator and, 52 h later, were washed with PBS and fixed for 15 min at room temperature with 1% formaldehyde/0.2% glutaraldehyde in PBS. The cells were then washed twice with PBS and incubated with 2 mM MgCl₂/5 mM potassium ferrocyanide/5 mM potassium ferricyanide/0.01 g of 5-bromo-4-chloro-3-indolyl β-D-galactoside (GIBCO)/1% *N,N*-dimethylformamide (Mallinckrodt) in PBS to detect the viral-encoded lacZ protein.

Infection of Cells with Virions Preloaded with TVB-EGF. Cells were plated at approximately 20% confluence on 12-well tissue culture plates before viral challenge. M5, B82, and T23 cells were incubated with 190 μl of (33×) MLV-lacZ (ALV-B), and M5:S3/T cells were incubated with 0.1 μl of these concentrated virions. M5, T23, and B82 cells were incubated separately with 0.5 μl, 1 μl, and 200 μl of (33×) MLV-lacZ (ALV-B)/TVB-EGF complexes, respectively. The cells were immediately placed at 37°C and, approximately 60 h later, were analyzed for infection by staining for lacZ activity as before.

To analyze virion thermostability, 0.5 μl of (50×) MLV-lacZ (ALV-B) or 2 μl of (50×) MLV-lacZ (ALV-B)/TVB-EGF complexes were incubated either on ice for 9 h (preincubation time = 0) or at 37°C for the time periods indicated and then returned to ice before addition to M5:S3/T cells or to M5 cells, respectively.

In the cocultivation experiment, human 293 cells producing MLV-GFP (ALV-B)/TVB-EGF complexes were placed, 16 h after transfection, in transwell inserts with a 0.4-μm pore size (CoStar). These transwell inserts were placed in six-well tissue culture plates that contained either M5 or B82 cells plated at approximately 20% confluence and incubated at 37°C. The transwell inserts were removed 56 h after the start of cocultivation, and the numbers of infected cells were determined by using flow cytometry to detect expression of GFP.

RESULTS

TVB-EGF Is a Bifunctional Reagent That Can Bind Both to Cell Surface EGF Receptors and to ALV-B SU. The TVB-EGF protein is comprised of the extracellular domain of the TVBS3 receptor for subgroups B and D ALV (ALV-B and ALV-D; refs. 22 and 29), fused via a glycine- and proline-rich linker region to the mature form of human EGF (30). TVB-EGF was produced in the extracellular supernatants of transiently transfected human 293 cells, and its production was confirmed by immunoblotting by using an EGF-specific antibody (Fig. 1A). Three predominant forms of TVB-EGF were detected (Fig. 1A), presumably resulting from differential glycosylation of the TVB domain as noted previously (22); the expected molecular mass of TVB-EGF without any N-linked carbohydrate residues is approximately 22 kDa.

Flow cytometric analysis was used to assess whether TVB-EGF is a bifunctional reagent that can bind simultaneously to cell surface EGF receptors and to the ALV-B SU subunit that is responsible for TVB binding. Cells were incubated with increasing amounts of supernatants that contained TVB-EGF and then incubated with a subgroup B-specific ALV SU-Ig fusion protein (22) followed by an FITC-conjugated secondary antibody. TVB-EGF bound in a saturable manner to transfected mouse L cells expressing kinase-deficient human EGFR (M5 cells) and to transfected mouse L cells expressing wild-type human EGFR (T23 cells; Fig. 1B). By contrast, the bridge protein did not bind to the parental mouse L cells, which lack EGF receptors (B82 cells), even at the highest amount of TVB-EGF added (Fig. 1B). In addition, TVB-EGF binding to M5 cells was specifically competed in the presence of recombinant EGF (Fig. 1C). Taken together, these data show that TVB-EGF binds specifically to ALV-B SU and to the ligand-binding regions of EGFR expressed on the surfaces of M5 and T23 cells.

TVB-EGF Mediates Viral Infection when Attached to Cell Surface EGFR. To determine whether TVB-EGF can facilitate viral entry when attached to cell surface EGFR, we asked whether this bridge protein could mediate infection by an MLV vector encoding lacZ and bearing ALV-B Env [designated MLV-lacZ (ALV-B)]. An MLV vector was chosen for this study, because, to date, these are the best characterized retroviral vectors used for infecting dividing cell types such as cancer cells (31). As expected, the MLV-lacZ (ALV-B) pseudotyped virus required cell surface TVB receptors for entry; in contrast to parental M5 cells, which were resistant to viral infection, transfected M5 cells (M5:S3/T) expressing a transmembrane form of TVBS3 were susceptible to infection by MLV-lacZ (ALV-B) (Table 1).

To assess whether TVB-EGF could mediate viral entry when bound to M5 cells, these cells were incubated with the bridge protein before challenge with MLV-lacZ (ALV-B). TVB-EGF rendered these cells highly susceptible to viral infection; the level of infection mediated by TVB-EGF was approximately 55% of that seen when control M5:S3/T cells were challenged with the same number of native virions (Table 1). M5 cells that were incubated with TVB-EGF were also very susceptible to infection by subgroup B-specific ALV-based vectors (data not shown). These results establish that TVB-EGF is a highly efficient mediator of targeted retroviral entry when attached to cell surface EGFR before viral challenge.

Virions Preloaded with TVB-EGF Specifically Infect Cells That Express EGFR. For most retroviral delivery applications, it would be desirable to preload the bridge protein onto virions, as opposed to cell surfaces, provided that such viral complexes retain their cell-type specificity. To determine whether retroviruses preloaded with TVB-EGF have this property, MLV-lacZ (ALV-B) virions were incubated with the bridge protein, and the resultant complexes were purified and used to infect M5, T23, and B82 cells.

The level of preloaded virus infection observed with M5 cells was extremely high and, in fact, exceeded the level obtained when the same number of native virions were used to infect the control M5:S3/T cells (Table 2). The level of preloaded virus infection of T23 cells was also high, representing approximately 29% of the level seen with native virus infection of M5:S3/T cells (Table 2). By contrast, the level of preloaded virus infection of B82 cells was low (Table 2). Indeed, similar low levels of infection were seen with B82, M5, and T23 cells that were challenged with native virions (Table 2), showing that these events are caused by an intrinsic ability of MLV-lacZ (ALV-B) to enter these cell types with low efficiency. Based on a comparison of the numbers of infection events obtained with cells that express or lack EGFR (Table 2), it seems that 99.97% of the preloaded virus infection events seen with M5 cells and 99.89% of those seen with T23 cells require the specific interaction of the virus-bound TVB-EGF and cell-surface EGFR.

Table 2. MLV-lacZ (ALV-B) virions preloaded with TVB-EGF specifically infect M5 and T23 cells with a high efficiency

Cell line	TVB-EGF	Viral titer per milliliter
B82	-	(6.6 ± 0.9) × 10 ²
	+	(5.0 ± 0.2) × 10 ²
M5	-	(8.8 ± 1.2) × 10 ²
	+	(2.2 ± 0.2) × 10 ⁶
T23	-	(2.1 ± 0.2) × 10 ²
	+	(4.5 ± 0.4) × 10 ⁵
M5:S3/T	-	(1.6 ± 0.04) × 10 ⁶

B82, M5, and T23 cells were challenged with MLV-lacZ (ALV-B) and MLV-lacZ (ALV-B)/TVB-EGF complexes. M5:S3/T cells were also challenged with MLV-lacZ (ALV-B). Infected cells were identified by staining for lacZ activity.

Preloaded Virions Can Be Generated Directly from Virus Packaging Cells. To determine whether virions preloaded with TVB-EGF could be produced from virus packaging cells, human 293 cells were cotransfected with plasmids encoding MLV-lacZ (ALV-B) and with different amounts of the pAB1 plasmid encoding TVB-EGF. The addition of increasing amounts of the pAB1 plasmid led to an increase in the production of TVB-EGF from the virus packaging cells (Fig. 2A). Virion/TVB-EGF complexes contained in the extracellular supernatants from virus-producing cells that were transfected with 0.01 μ g, 0.1 μ g, or 1 μ g of pAB1 plasmid DNA were able to infect M5 cells but not B82 cells (Fig. 2B). However, the level of infection of M5 cells was substantially reduced when 1 μ g of pAB1 plasmid DNA was transfected (Fig. 2B). Given the relationship between the amount of pAB1 plasmid DNA transfected and the amount of TVB-EGF produced (Fig. 2A), we reasoned that this inhibitory effect might be caused by the production of excess levels of the bridge protein, which might act as a competitive inhibitor of preloaded virus entry. To test this possibility, virion/TVB-EGF complexes were purified from unbound bridge protein in the extracellular supernatants by ultracentrifugation and were concentrated 100-fold before infection of M5 and B82 cells. With M5 cells, the infectious titers obtained with these complexes purified from cells transfected with 0.01 μ g and 0.1 μ g of pAB1 plasmid DNA were similar to those expected from the 100-fold concentration effect (Fig. 2C). Indeed, it is noteworthy that, by using 0.01 μ g of pAB1 plasmid DNA, the purified preloaded

virions infected M5 cells 3,300-fold more efficiently than B82 cells, which lack EGFR (Fig. 2C). This level is consistent with the specificity of infection obtained when TVB-EGF was preloaded onto native virions (Table 2). By contrast, the titer obtained with virions purified from cells transfected with 1 μ g of pAB1 plasmid DNA was approximately 45-fold higher than that expected from the concentration effect alone (Fig. 2C), consistent with the idea that excess amounts of the bridge protein must be removed for efficient infection by these preloaded viruses.

As an independent test of the specificity of the preloaded virions, virus packaging cells were generated that produced TVB-EGF and MLV (ALV-B) particles encoding GFP. These cells were cocultivated with either M5 or B82 cells, and the target cells were analyzed for infection by flow cytometry. After 56 h of cocultivation, approximately 20% of the M5 cells were infected by virus (Fig. 2D Left). In contrast, there was no discernable infection of B82 cells under the same conditions (Fig. 2D Right). These results underscore the strict cell-type-specific infection of the preloaded virions.

The fact that preloaded virions were infectious, even when produced from virus packaging cells, indicated that these viral complexes must be somewhat stable at 37°C. To investigate their thermostability, preloaded viruses were incubated at 37°C for different periods of time before addition to M5 cells. For control purposes, these experiments were also performed by using native virions that were then used to infect the control M5:S3/T cells. These studies showed that both the native




FIG. 2. TVB-EGF-loaded virions produced directly from virus packaging cells infect M5 cells specifically. Human 293 cells were transfected with fixed amounts of plasmids encoding MLV-lacZ (ALV-B) and with variable amounts of plasmid pAB1 encoding TVB-EGF. (A) Aliquots of extracellular supernatants taken from these cells were monitored for TVB-EGF production by immunoblotting analysis by using a subgroup B ALV SU-Ig fusion protein (22) and a horseradish peroxidase-coupled secondary antibody. (B) M5 and B82 cells were challenged with MLV-lacZ (ALV-B) virions produced from cells that were cotransfected with the amounts of pAB1 plasmid DNA indicated, and the resultant numbers of infected cells were determined by lacZ staining. (C) MLV-lacZ (ALV-B)/TVB-EGF complexes in B were purified from unbound TVB-EGF and concentrated 100-fold before infection. Gray bars represent the expected infectious viral titer based on the 100-fold concentration effect (as compared with those numbers obtained in B). Black bars represent the actual infectious titers observed with the purified virion/TVB-EGF complexes. (D) M5 cells or B82 cells were cocultivated with human 293 cells that produce MLV-GFP (ALV-B)/TVB-EGF complexes. Flow cytometric profiles for M5 (Left) and B82 (Right) are shown after 0 or 56 h of cocultivation.

virions (Fig. 3A) and preloaded virions (Fig. 3B) were inactivated when incubated for several hours at 37°C. It is clear from these data, however, that the preloaded virions are at least as stable as native virions when preincubated at 37°C for a short time period.

DISCUSSION

In this report, we have shown that TVB-EGF, a model TVB-ligand bridge protein, can be used to target infection by retroviral vectors to cells that express EGFR. TVB-EGF that was bound to M5 cell surface EGFR before viral challenge efficiently mediated infection by a pseudotyped MLV vector bearing the ALV-B Env protein, whereas there was no obvious infection of B82 cells, which lack EGFR. Indeed, the level of infection obtained with M5 cells was approximately one-half of that seen with control TVB-expressing M5 cells challenged with the same number of native virions.




FIG. 3. MLV-lacZ (ALV-B)/TVB-EGF complexes are stable at 37°C. MLV-lacZ (ALV-B) (A) or MLV-lacZ (ALV-B Env)/TVB-EGF (B) complexes were incubated at 37°C for different time intervals before addition to M5:S3/T cells or to M5 cells, respectively. The number of infected cells was measured by lacZ staining. The results shown reflect the percentage remaining of the starting virus titer (at $t = 0$). The starting titer of MLV-lacZ (ALV-B) was approximately 2×10^5 lacZ-positive colonies per ml and that of the virion/TVB-EGF complexes was approximately 3×10^4 lacZ-positive colonies per ml.

The most important activity of TVB-EGF was that it also supported efficient viral entry when attached to virions before their addition to cells. These preloaded viruses were produced successfully either by mixing native virions with extracellular supernatants containing TVB-EGF or instead by coexpressing the bridge protein in virus packaging cells. Virions preloaded with TVB-EGF specifically infected M5 and T23 cells with an efficiency that exceeded or closely approximated that seen with control TVB-expressing M5 cells challenged with native virions. In these experiments, the preloaded virions preferentially infected M5 cells as compared with T23 cells (Table 2). The reason for this difference between the two cell types is currently under investigation and might be linked to differences in rates of endocytosis and/or trafficking of kinase-deficient EGFR, as opposed to wild-type forms of EGFR, as discussed previously (20).

In contrast to M5 cells and T23 cells, B82 cells were only infected at a low level by virions preloaded with TVB-EGF. It is extremely unlikely that this small number of infection events was caused by the fact that these virions were preloaded with the retroviral receptor-ligand bridge protein before addition to cells, because similar numbers of infected cells were seen when B82, T23, and M5 cells were challenged with native virions. Instead, it seems that this low level of nonspecific infection is caused by an intrinsic ability of the MLV pseudotyped viruses to enter these cells with a low efficiency.

An unexpected finding of these studies was that virions bound to TVB-EGF were at least as stable as native virions when incubated at 37°C before addition to cells. Based on previous studies of ALV-A Env/TVA interactions, we had expected that MLV-lacZ (ALV-B) pseudotypes preloaded with TVB-EGF might be unstable under these conditions, because TVA binding induces rapid temperature-dependent conformational changes in a soluble ALV-A Env protein that are similar to those expected to give rise to the fusion-active form of the viral glycoprotein (32, 33). In the absence of an appropriate target cell membrane, these receptor-induced structural changes in Env might be expected to inactivate the viral glycoprotein in much the same way seen with low-pH-treated influenza virus hemagglutinin glycoproteins (34). Consistent with this idea, we have not been able to efficiently infect M5 cells with MLV-lacZ (ALV-A) vectors that are preloaded with TVA-EGF (data not shown). Although the precise defect of these TVA-EGF-loaded viruses remains to be established, these data indicate an apparent difference between ALV-A and ALV-B Env-receptor interactions and show that these types of bridge proteins can be useful tools for studying parameters that influence the efficiency of retroviral entry in addition to their use as viral targeting reagents.

Another important result obtained from these studies was that TVB-EGF-loaded MLV vectors bearing ALV-B Env can be stably produced from virus packaging cells while retaining their targeting specificity. This result opens up the possibility of targeting a variety of different retroviral vectors (e.g., those based on ALV, MLV, or lentiviruses) by simply expressing both ALV-B Env and a TVB-ligand bridge protein in cells that produce these viral vectors. This possibility, in turn, could have important implications for the delivery of retroviral vectors to specific cell types *in vivo*. Previously, it was shown that infection of cancer cells *in vivo* by MLV vectors could be achieved by direct injection of virus packaging cells (35). The approach described in this study could extend the specificity of infection that can be achieved by this method by introducing cells that produce viral vectors that are preloaded with TVB-ligand bridge proteins with defined target cell specificities.

We thank Gordon Gill for providing the mouse L cell lines, John Daley at the Dana-Farber Cancer Institute for assistance with flow cytometry, and Mayra Lorenzo for her assistance in plasmid construction. We also thank John Naughton for help with the figures, and

members of the Young lab, Richard Mulligan, and John Collier for critically reading the manuscript. This work was supported by National Institutes of Health Grant CA 70810, by Department of the Army Grant DAMD17-98-1-8488, and by a Harvard Medical School Funds for Discovery Award.

1. Neda, H., Wu, C. H. & Wu, G. Y. (1991) *J. Biol. Chem.* **266**, 14143-14146.
2. Roux, P., Jeanteur, P. & Piechaczyk, M. (1989) *Proc. Natl. Acad. Sci. USA* **86**, 9079-9083.
3. Etienne-Julan, M., Roux, P., Carillo, S., Jeanteur, P. & Piechaczyk, M. (1992) *J. Gen. Virol.* **73**, 3251-3255.
4. Valsesia-Wittmann, S., Drynda, A., Deleage, G., Aumailley, M., Heard, J. M., Danos, O., Verdier, G. & Cosset, F. L. (1994) *J. Virol.* **68**, 4609-4619.
5. Valsesia-Wittmann, S., Morling, F. J., Nilson, B. H., Takeuchi, Y., Russell, S. J. & Cosset, F. L. (1996) *J. Virol.* **70**, 2059-2064.
6. Kasahara, N., Dozy, A. M. & Kan, Y. W. (1994) *Science* **266**, 1373-1376.
7. Han, X., Kasahara, N. & Kan, Y. W. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 9747-9751.
8. Matano, T., Odawara, T., Iwamoto, A. & Yoshikura, H. (1995) *J. Gen. Virol.* **76**, 3165-3169.
9. Cosset, F. L., Morling, F. J., Takeuchi, Y., Weiss, R. A., Collins, M. K. & Russell, S. J. (1995) *J. Virol.* **69**, 6314-6322.
10. Nilson, B. H., Morling, F. J., Cosset, F. L. & Russell, S. J. (1996) *Gene Ther.* **3**, 280-286.
11. Chu, T. H. & Dornburg, R. (1995) *J. Virol.* **69**, 2659-2663.
12. Chu, T. H., Martinez, I., Sheay, W. C. & Dornburg, R. (1994) *Gene Ther.* **1**, 292-299.
13. Somia, N. V., Zoppe, M. & Verma, I. M. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 7570-7574.
14. Russell, S. J., Hawkins, R. E. & Winter, G. (1993) *Nucleic Acids Res.* **21**, 1081-1085.
15. Marin, M., Noel, D., Valsesia-Wittman, S., Brockly, F., Etienne-Julan, M., Russell, S., Cosset, F. L. & Piechaczyk, M. (1996) *J. Virol.* **70**, 2957-2962.
16. Ager, S., Nilson, B. H., Morling, F. J., Peng, K. W., Cosset, F. L. & Russell, S. J. (1996) *Hum. Gene Ther.* **7**, 2157-2164.
17. Jiang, A., Chu, T. H., Nocken, F., Cichutek, K. & Dornburg, R. (1998) *J. Virol.* **72**, 10148-10156.
18. Cosset, F. L. & Russell, S. J. (1996) *Gene Ther.* **3**, 946-956.
19. Verma, I. M. & Somia, N. (1997) *Nature (London)* **389**, 239-241.
20. Snitkovsky, S. & Young, J. A. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 7063-7068.
21. Gullick, W. J. (1998) *Biochem. Soc. Symp.* **63**, 193-198.
22. Brojatsch, J., Naughton, J., Rolls, M. M., Zingler, K. & Young, J. A. (1996) *Cell* **87**, 845-855.
23. Ory, D. S., Neugeboren, B. A. & Mulligan, R. C. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 11400-11406.
24. Chen, W. S., Lazar, C. S., Poenie, M., Tsien, R. Y., Gill, G. N. & Rosenfeld, M. G. (1987) *Nature (London)* **328**, 820-823.
25. Glenny, J. R., Jr., Chen, W. S., Lazar, C. S., Walton, G., Zokas, L. M., Rosenfeld, M. G. & Gill, G. N. (1988) *Cell* **675-684**.
26. Adkins, H. B., Brojatsch, J., Naughton, J., Rolls, M. M., Pesenti, J. M. & Young, J. A. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 11617-11622.
27. Landau, N. R. & Littman, D. R. (1992) *J. Virol.* **66**, 5110-5115.
28. Wool-Lewis, R. J. & Bates, P. (1998) *J. Virol.* **72**, 3155-3160.
29. Smith, E. J., Brojatsch, J., Naughton, J. & Young, J. A. (1996) *J. Virol.* **72**, 3501-3503.
30. Stern, D. F., Hare, D. L., Cecchini, M. A. & Weinberg, R. A. (1987) *Science* **235**, 321-324.
31. Runnebaum, I. B. (1997) *Anticancer Res.* **17**, 2887-2890.
32. Hernandez, L. D., Peters, R. J., Delos, S. E., Young, J. A., Aggeler, J. & White, J. M. (1997) *J. Cell Biol.* **139**, 1455-1464.
33. Damico, R. L., Crane, J. & Bates, P. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 2580-2585.
34. Wharton, S. A., Calder, L. J., Ruigrok, R. W., Skehel, J. J., Steinhauer, D. A. & Wiley, D. C. (1995) *EMBO J.* **14**, 240-245.
35. Hurford, R. K., Jr., Dranoff, G., Mulligan, R. C. & Tepper, F. (1995) *Nat. Genet.* **10**, 430-435.

RETROVIRAL VECTORS PRELOADED WITH A VIRAL RECEPTOR-
LIGAND BRIDGE PROTEIN ARE TARGETED TO SPECIFIC CELL
TYPES

Adrienne L. Boerger and John A.T. Young

Department of Microbiology and Molecular Genetics,
Harvard Medical School

Successful targeting methods represent a major hurdle to the use of retroviral vectors in cell-specific gene delivery applications. We recently described a novel and efficient approach for retroviral targeting using a retroviral receptor-ligand bridge protein. The bridge protein is a bifunctional reagent that binds to specific cell surface receptors and to the viral Env protein, facilitating viral entry [S. Snitkovsky, J. A. Young, *Proc Natl Acad Sci U S A* 95, 7063-8 (1998)]. The functional activities of another type of bridge protein, designated TVB-EGF, have now been characterized. This protein is comprised of the tumor necrosis factor receptor (TNFR)-related extracellular domain of the TVB receptor for subgroup B avian leukosis virus (ALV-B) fused to epidermal growth factor (EGF). EGF was chosen because interactions with the EGF receptor have been biochemically well characterized. In addition, members of the EGF receptor family are often upregulated or mutated in relevant cell types such as cancer cells. The TVB-EGF bridge protein mediates infection by a subgroup B ALV vector, as well as a murine leukemia virus vector bearing ALV-B Env, when attached to cell surface EGF receptors (EGFR) before viral challenge. Most notably, the TVB-EGF bridge protein can also facilitate targeted viral infection when preloaded onto virions as opposed to cell surfaces, and the preloaded virions are remarkably stable at 37°C. Moreover, these preloaded virions can be produced directly from viral packaging cells when the viral proteins are co-expressed with the bridge protein. These data suggest a novel approach for targeting retroviral vectors to specific cell types *in vivo* by introducing preloaded virus directly, or cells that produce the preloaded virions to ensure highly efficient gene delivery to relevant cell types.